How can we address the uncertainties regarding the potential clinical utility of polygenic score-based tests?
Future Medicine Ltd
MetadataShow full item record
Moorthie, S., Hall, A., Babb de Villiers, C., Janus, J., Brigden, T., Blackburn, L., & Kroese, M. (2022). How can we address the uncertainties regarding the potential clinical utility of polygenic score-based tests?. Per Med, 0 (0) https://doi.org/10.2217/pme-2021-0148
As common low penetrance variants associated with diseases are uncovered, attempts continue to be made to harness this knowledge for improving healthcare. Polygenic scores have been developed as the mechanism by which knowledge of common variants can be used to investigate genetic contributions to disease risk. They serve as a biomarker to provide an estimate of the genetic liability for a particular disease. Discussion continues as to whether polygenic scores are a useful biomarker and their readiness for incorporation into clinical and public health practice. In this paper, we investigate the key challenges that need to be addressed, in the description and assessment of the clinical utility of polygenic score-based tests for use in clinical and public health practice.
Review, biomarker, clinical utility, common disorders, genetic test evaluation, personalized medicine, polygenic scores, regulation, risk prediction, risk stratification, SNPs
External DOI: https://doi.org/10.2217/pme-2021-0148
This record's URL: https://www.repository.cam.ac.uk/handle/1810/335005